Inflammatory Bowel Disease- What do I do if I am pregnant or breastfeeding?


Inflammatory bowel disease (IBD) in pregnant women increases the risk of preterm birth, low birth weight and miscarriages- however, the evidence is not as strong for an increased risk of congenital abnormalities (malformations)

Pregnant patients with inflammatory bowel disease that are in remission at the time of conception are likely to remain in remission during pregnancy but up to one-third (1/3) may have a relapse during the pregnancy.

Women with IBD who are planning a pregnancy should try to conceive at a time when the disease is in remission. That would be the ideal strategy. Female and male IBD patients should note that their disease does not reduce fertility; the observed childlessness in IBD patients is due to voluntary choices often based on incorrect patient beliefs rather than physiologic or organic causes.!  So don’t be afraid to do start a family.

Most inflammatory bowel disease medications, except methotrexate, should not be discontinued at conception or while breastfeeding since their cessation might lead to disease flares; the risk of the untreated disease (preterm birth, miscarriage) is often greater than the risk of most available medications.!  Let’s keep that in mind!

■             Aminosalicylates are considered low risk for use in pregnancy or while breastfeeding. Due to potential antifolate effects, women taking sulfasalazine may be safely switched to 5-ASA or are generally advised to supplement with 2 mg of folic acid daily starting before conception and continuing throughout their pregnancy.!

■             Corticosteroids are considered safe and may be continued in pregnancy if indicated; however, use them with caution in the 1st trimester since they have been associated with an increased, though still low, risk of oral clefts in the newborn.! Corticosteroids may be used at any stage of pregnancy (including 1st trimester) if benefits outweigh potential risks, e.g., during disease flares. Prednisone and prednisolone are considered compatible with breastfeeding.!

■             Cyclosporine is not usually used for treatment of IBD but is considered to have an overall low risk during pregnancy. Do not use cyclosporine during breastfeeding!

Azathioprine and 6-mercaptopurine (6-MP) are considered low risk during pregnancy despite the conflicting safety data. Azathioprine and 6-MP are generally considered compatible with breastfeeding but it is considered safest to separate breastfeeding by a few hours from dosing.

■             Methotrexate is contraindicated in pregnancy and breastfeeding owing to its teratogenic and cytotoxic effects. Use effective contraception if taking methotrexate. Discontinue the drug 3-6 months prior to attempted conception.

■             Use of adalimumab (Humira®) golimumab (Simponi®) and infliximab (Remicade®) in pregnant patients with inflammatory bowel disease is considered low risk during the 1st and 2nd trimesters; however, there are concerns about immunosuppression in the newborn if administered during the 3rd trimester! In patients with active inflammatory bowel disease and those at high risk of relapse of active IBD. the risks of uncontrolled disease activity to mother and child (e.g., preterm birth, low birth weight and miscarriage) may outweigh the potential toxicity of anti- TNF-alpha medications, e.g., serious systemic infections. Therefore, expert consensus statements recommend these therapies be continued during the 3rd trimester, particularly in those with a history of difficult to control disease, but consideration can be made for discontinuing anti- TNF-alpha agents around the start of the 3rd trimester if the patient is in long-term remission.

Adalimumab, golimumab and infliximab are actively transported across the placenta in the 3rd trimester and may remain in the newborn’s blood for up to 6 months postdelivery. Therefore, unless serum anti-TNF-alpha levels in the newborn are proven negative, administration of any live vaccines (e.g., rotavirus vaccine) should be delayed until at least 6 months of age. Use of anti- TNF-alpha therapies(1) is compatible with breastfeeding, as levels detected in breast milk are minimal to nothing.

■             The safety of using ustekinumab or vedolizumab during pregnancy and breastfeeding is currently unknown.

■             Metronidazole has a low teratogenic risk when used during pregnancy, but should not be used while patient is breastfeeding because it transfers to breast milk.I44! Avoid prolonged metronidazole use in pregnant patients.

■             Alternatives to ciprofloxacin should be considered for pregnant and breastfeeding women

(1) TNF inhibitors are drugs that help stop inflammation. They’re used to treat diseases like rheumatoid arthritis (RA), juvenile arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, ulcerative colitis (UC), and Crohn’s disease. They’re also called TNF blockers, biologic therapies, or antiTNF drugs

Anti _TNF
Anti _TNF

Leave a Reply